Nuclear export receptor CRM1 recognizes diverse conformations in nuclear export signals
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Nuclear export receptor CRM1 recognizes diverse conformations in nuclear export signals
Authors
Keywords
-
Journal
eLife
Volume 6, Issue -, Pages -
Publisher
eLife Sciences Organisation, Ltd.
Online
2017-03-10
DOI
10.7554/elife.23961
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B-cell lymphoma
- (2016) Fabrice Jardin et al. AMERICAN JOURNAL OF HEMATOLOGY
- On the acquisition and analysis of microscale thermophoresis data
- (2016) Thomas H. Scheuermann et al. ANALYTICAL BIOCHEMISTRY
- The Second-Generation Exportin-1 Inhibitor KPT-8602 Demonstrates Potent Activity against Acute Lymphoblastic Leukemia
- (2016) Thomas Vercruysse et al. CLINICAL CANCER RESEARCH
- Detection and prognostic value of recurrent exportin 1 mutations in tumor and cell-free circulating DNA of patients with classical Hodgkin lymphoma
- (2016) V. Camus et al. HAEMATOLOGICA
- Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Combination With Fludarabine and Cytarabine, in Pediatric Relapsed or Refractory Acute Leukemia
- (2016) Thomas B. Alexander et al. JOURNAL OF CLINICAL ONCOLOGY
- First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors
- (2016) Albiruni R. Abdul Razak et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma
- (2016) Mrinal M. Gounder et al. JOURNAL OF CLINICAL ONCOLOGY
- Next-generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematological malignancies
- (2016) Z A Hing et al. LEUKEMIA
- XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer
- (2016) Jimi Kim et al. NATURE
- Fully Blind Docking at the Atomic Level for Protein-Peptide Complex Structure Prediction
- (2016) Chengfei Yan et al. STRUCTURE
- Detection and prognostic value of recurrent exportin 1 mutations in tumor and cell-free circulating DNA of patients with classical Hodgkin lymphoma
- (2016) V. Camus et al. HAEMATOLOGICA
- Fully Blind Peptide-Protein Docking with pepATTRACT
- (2015) Christina E.M. Schindler et al. STRUCTURE
- A deep proteomics perspective on CRM1-mediated nuclear export and nucleocytoplasmic partitioning
- (2015) Koray Kırlı et al. eLife
- Structural determinants of nuclear export signal orientation in binding to exportin CRM1
- (2015) Ho Yee Joyce Fung et al. eLife
- Selective inhibitors of nuclear export (SINE) as novel therapeutics for prostate cancer
- (2015) Janet Mendonca et al. Oncotarget
- LocNES: a computational tool for locating classical NESs in CRM1 cargo proteins
- (2014) Darui Xu et al. BIOINFORMATICS
- Selective inhibitors of nuclear export (SINE)– a novel class of anti-cancer agents
- (2014) Kaushal Parikh et al. Journal of Hematology & Oncology
- XPO1 (CRM1) Inhibition Represses STAT3 Activation to Drive a Survivin-Dependent Oncogenic Switch in Triple-Negative Breast Cancer
- (2014) Y. Cheng et al. MOLECULAR CANCER THERAPEUTICS
- NESmapper: Accurate Prediction of Leucine-Rich Nuclear Export Signals Using Activity-Based Profiles
- (2014) Shunichi Kosugi et al. PLoS Computational Biology
- KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia
- (2013) Julia Etchin et al. BRITISH JOURNAL OF HAEMATOLOGY
- Structural diversity of calmodulin binding to its target sites
- (2013) Henning Tidow et al. FEBS Journal
- CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications
- (2013) Y-T Tai et al. LEUKEMIA
- A Unified Conformational Selection and Induced Fit Approach to Protein-Peptide Docking
- (2013) Mikael Trellet et al. PLoS One
- Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia
- (2012) R. Lapalombella et al. BLOOD
- CRM1 Blockade by Selective Inhibitors of Nuclear Export Attenuates Kidney Cancer Growth
- (2012) Hiromi Inoue et al. JOURNAL OF UROLOGY
- Identification of CRM1-dependent Nuclear Export Cargos Using Quantitative Mass Spectrometry
- (2012) Ketan Thakar et al. MOLECULAR & CELLULAR PROTEOMICS
- Sequence and structural analyses of nuclear export signals in the NESdb database
- (2012) Darui Xu et al. MOLECULAR BIOLOGY OF THE CELL
- NESdb: a database of NES-containing CRM1 cargoes
- (2012) Darui Xu et al. MOLECULAR BIOLOGY OF THE CELL
- Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia
- (2011) Xose S. Puente et al. NATURE
- Prediction of leucine-rich nuclear export signal containing proteins with NESsential
- (2011) Szu-Chin Fu et al. NUCLEIC ACIDS RESEARCH
- Rosetta FlexPepDock ab-initio: Simultaneous Folding, Docking and Refinement of Peptides onto Their Receptors
- (2011) Barak Raveh et al. PLoS One
- NES consensus redefined by structures of PKI-type and Rev-type nuclear export signals bound to CRM1
- (2010) Thomas Güttler et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Structural basis for leucine-rich nuclear export signal recognition by CRM1
- (2009) Xiuhua Dong et al. NATURE
- Crystal Structure of the Nuclear Export Receptor CRM1 in Complex with Snurportin1 and RanGTP
- (2009) T. Monecke et al. SCIENCE
- A Novel Main Chain Motif in Proteins Bridged by Cationic Groups: The Niche
- (2008) Gilleain M. Torrance et al. JOURNAL OF MOLECULAR BIOLOGY
- Nuclear Export Signal Consensus Sequences Defined Using a Localization-Based Yeast Selection System
- (2008) Shunichi Kosugi et al. TRAFFIC
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started